What we measure
The 2018 Index analyses how 20 of the world's largest pharmaceutical companies are addressing access to medicine in 106 low- to middle-income countries for 77 diseases, conditions and pathogens. Find out more about the scope of the Index research.
How we measure
The Index evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to make change, such as R&D and pricing. Find out more about the analytical framework and areas of evaluation.
The context
Millions of people today cannot access medicine when they need to. This can be due to high prices, to empty pharmacy shelves, or other factors. Find out more about the situation and how the Index stimulates pharmaceutical companies to help turn it around.
Put the Index to use
The Access to Medicine Index is a tool for change. It identifies what is working where and why to provide blueprints for expanding good practice in pricing, licensing, R&D and more. Find out who is using this research and how it can help your work.
The research process
The Foundation’s team of researchers measures company behaviour using a rigorous process of data-collection, verification, scoring and analysis. Find out more about what these phases involve.
How we work with experts
Every two years, the Index methodology is refined based on a targeted review of how stakeholders view pharma’s role in access to medicine. Find out more about this review and the experts involved.
